FUTURES 2025 Breakout Session: New Therapeutic Approaches

05.24.2025

Frank Gleeson, CEO of Satellos, presented in the “New Therapeutic Approaches” session at the 2025 CureDuchenne FUTURES Conference, providing a explanation of the science behind SAT-3247, Phase 1 updates, and what’s ahead for Phase 2.

In The News

The Genetics Podcast banner with Frank Gleeson's face featured.
06.05.2025

The Genetics Podcast: Targeting Regeneration to Tackle Duchenne Muscular Dystrophy
Frank Gleeson, co-founder and CEO of Satellos, presenting at the CureDuchenne FUTURES conference
05.24.2025

FUTURES 2025 Breakout Session: New Therapeutic Approaches
04.10.2025

Drug Discovery News: A New Approach to Treating Duchenne Muscular Dystrophy
04.05.2025

Base to Base Biotech Podcast
In the News 03.20.2025

NeurologyLive: SAT-3247 and Restoring Muscle Regeneration in Duchenne Muscular Dystrophy
In the News 01.23.2025

Drug Target Review: SAT-3247, a new small molecule approach to Duchenne muscular dystrophy
In the News 12.04.2024

PropThink Digital Conferences: Duchenne KOL Investor Webinar
In the News 11.26.2024

Ottawa Citizen: An Ottawa Scientist's Discovery Offers Rare Hope for Patients with Devastating Genetic Disease
In the News 11.20.2024

PharmaShots: Enhancing DMD Care, a Q&A with Phil Lambert from Satellos
In the News 10.07.2024

Inside Precision Medicine: In Conversation with Frank Gleeson
Press Release 09.18.2024

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
In the News 08.08.2024

Clinical Trials Arena: Satellos to Commence Phase 1 Trial for DMD Drug
Press Release 08.08.2024

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
In the News 07.02.2024

Pharmaphorum Podcast: The Power and Potential of Regenerative Medicine
Press Release 07.11.2024

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
In the News 06.24.2024

Drug Target Review Podcast: Small Molecules for Regenerative Medicine
In the News 05.30.2024

Satellos Receives Company of the Year Award from Life Sciences Ontario
Press Release 05.28.2024

Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
In the News 05.23.2024

Radius Research Webinar | Satellos Product Development and Milestones
In the News 04.18.2024

RareCast: A Small Molecule Therapy to Regenerate Muscle in People with DMD
In the News 04.17.2024

Destroy Duchenne Podcast: Pioneering Duchenne Muscular Dystrophy Treatment with Satellos | Elijah Stacy & Dr. Rudnicki
In the News 03.21.2024

Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48
Press Release 03.04.2024

Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
In the News 02.20.2024

MD News Today: SAT-3247 Improves Muscle Function in FSHD Mouse Model
Satellos MDA Curtain Raiser Header Image for Press Release
Press Release 02.20.2024

Satellos Announces Upcoming Presentations at the 2024 MDA Clinical & Scientific Conference
Satellos TSX 50 2024
Press Release 02.21.2024

Satellos Recognized as a Top 50 TSX Venture Exchange Company
Press Release 02.14.2024

Satellos to Commence Trading on the Toronto Stock Exchange
Press Release 02.13.2024

Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
In the News 01.24.2024

Satellos CEO Frank Gleeson Speaks with pharmaphorum at JPM24
Press Release 01.16.2024

Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
In the News 01.15.2024

Life Sciences Ontario Announces Recipients of 2024 LSO Awards
Press Release 11.14.2023

SATELLOS Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
In the News 10.10.2023

Drug Target Review: Advancing Muscle Repair
Back